iScience (Aug 2024)

Glycogen synthase kinase 3 inhibition controls Mycobacterium tuberculosis infection

  • Sandra Peña-Díaz,
  • Joseph D. Chao,
  • Celine Rens,
  • Hasti Haghdadi,
  • Xingji Zheng,
  • Keegan Flanagan,
  • Mary Ko,
  • Tirosh Shapira,
  • Adrian Richter,
  • Danay Maestre-Batlle,
  • Julio Ortiz Canseco,
  • Maximiliano Gabriel Gutierrez,
  • Khanh Dao Duc,
  • Steven Pelech,
  • Yossef Av-Gay

Journal volume & issue
Vol. 27, no. 8
p. 110555

Abstract

Read online

Summary: Compounds targeting host control of infectious diseases provide an attractive alternative to antimicrobials. A phenotypic screen of a kinase library identified compounds targeting glycogen synthase kinase 3 as potent inhibitors of Mycobacterium tuberculosis (Mtb) intracellular growth in the human THP-1 cell line and primary human monocytes-derived macrophages (hMDM). CRISPR knockouts and siRNA silencing showed that GSK3 isoforms are needed for the growth of Mtb and that a selected compound, P-4423632 targets GSK3β. GSK3 inhibition was associated with macrophage apoptosis governed by the Mtb secreted protein tyrosine phosphatase A (PtpA). Phospho-proteome analysis of macrophages response to infection revealed a wide array of host signaling and apoptosis pathways controlled by GSK3 and targeted by P-4423632. P-4423632 was additionally found to be active against other intracellular pathogens. Our findings strengthen the notion that targeting host signaling to promote the infected cell’s innate antimicrobial capacity is a feasible and attractive host-directed therapy approach.

Keywords